Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Syndax Pharmaceuticals, Inc. - Common Stock
(NQ:
SNDX
)
20.10
+0.81 (+4.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Syndax Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Syndax Announces Participation in September Investor Conferences
Today 7:00 EDT
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax (SNDX) Q2 2026 Earnings Call Transcript
↗
August 11, 2026
Revenue surged 92% year-over-year to $72.8 million, driven by Revuforj and Niktimvo.
Via
The Motley Fool
Topics
Earnings
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 05, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Q2 Earnings Call Highlights
↗
August 04, 2026
Syndax Pharmaceuticals (NASDAQ:SNDX) reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic...
Via
MarketBeat
Topics
Earnings
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Drop as Q2 Revenue and EPS Miss Estimates
↗
August 04, 2026
Via
Chartmill
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Stock Slides After Q1 Revenue Misses Street Forecasts Despite 224% Growth
↗
April 30, 2026
Via
Chartmill
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
August 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
July 28, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
↗
July 14, 2026
Syndax Pharmaceuticals (NASDAQ:SNDX) used a company R&D event to outline expansion plans for its approved medicines Revuforj and Niktimvo while introducing two pipeline assets aimed at non-small cell...
Via
MarketBeat
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
July 14, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 01, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template
↗
March 26, 2026
Via
Chartmill
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
June 11, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
June 11, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
June 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
June 02, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
June 01, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
May 21, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Participation in Upcoming Investor Conferences
May 20, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
May 12, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 06, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
April 30, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
April 24, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 03, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
↗
March 21, 2026
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
↗
March 21, 2026
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
↗
March 21, 2026
This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
↗
March 21, 2026
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
↗
March 21, 2026
This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.